- After the hump: Pfizer-AstraZeneca combo on downhill slope
- US Capitol Capsule: Rare disease sector matures; FDA keeping pace?
- Pfizer promotes 'underappreciated' R&D pipeline
- Scrip 100: Statin debate set to run and run
COMMENT Other Informa Comment
- PROFILE: AstraZeneca's Mene Pangalos on yin and yang, not believing your own press, and his part in Soriot's vision
- Profile: Fred Hassan, pharma titan, gooseberry picker and secret geography geek